Loading...
menu
Search
AI Trading Bot
Features
Markets
News
Resources
Pricing
Home
ETF
XNCR
XNCR
-
Add to Watchlist
$
0.000
0.000
(
0.000%
)
At close
0.000
(
0.000%
)
Aft-market
ET
$
0.000
0.000
(
0.000%
)
At close
0.000
(
0.000%
)
Aft-market
ET
Overview
Technical
News
XNCR News
Xencor Lowers Outlook After Royalty Dispute
5d ago
seekingalpha
Xencor Lowers Revenue Outlook for Ultomiris Royalties
5d ago
Benzinga
Xencor Q4 Earnings Beat Expectations Despite Revenue Decline
Feb 25 2026
seekingalpha
Incyte reveals EU authorization for lymphoma treatment developed in partnership with Xencor
Dec 17 2025
SeekingAlpha
Xencor Extends Ultomiris Patent to 2028, Anticipates $100M to $120M in Additional Revenue
Dec 09 2025
Newsfilter
JP Morgan Keeps Overweight Rating on Xencor, Reduces Price Target to $18
Nov 06 2025
Benzinga
RBC Capital Reaffirms Outperform Rating for Xencor and Increases Price Target to $19
Nov 06 2025
Benzinga
Could Xencor's (XNCR) Preliminary Cancer Findings Indicate a New Advantage in Its Innovation Approach?
Oct 28 2025
Yahoo Finance
Xencor Unveils Preliminary Findings for XmAb819, a Novel ENPP3 x CD3 Bispecific T-Cell Engager Targeting Clear Cell Renal Cell Carcinoma
Oct 24 2025
Newsfilter
Xencor to Hold Webcast and Conference Call to Review Preliminary Findings from the Ongoing Phase 1 Dose-Escalation Trial of XmAb819 in Advanced Clear Cell Renal Cell Carcinoma
Oct 21 2025
Newsfilter
Natural Killer Cell Treatments Drive $254B Shift in Immunotherapy Market
Oct 17 2025
Newsfilter
Strategies for Profiting from Tax-Loss Selling Before Year-End
Oct 02 2025
MarketWatch
Our Calculations Show RWJ Could Reach $54
Sep 25 2025
NASDAQ.COM
Erasca, Candle, Xencor Decline Following BofA Downgrade Due to Absence of Immediate Catalysts
Sep 03 2025
SeekingAlpha
Top Analysts Recommend 3 Best Stocks to Purchase Now, 9/3/2025
Sep 03 2025
TipRanks
In-Depth Insights: Four Analysts Weigh In on Xencor Stock
Sep 02 2025
Benzinga
Show More News
